Literature DB >> 18032741

Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laser-scanning microscopy study.

Anitha Nimmagadda1, Hee-Pyoung Park, Ricardo Prado, Myron D Ginsberg.   

Abstract

BACKGROUND AND
PURPOSE: High-dose human albumin is robustly neuroprotective in preclinical ischemia models and is currently in phase III clinical trial for acute ischemic stroke. To explore the hypothesis that albumin's protective effect is mediated in part by salutary intravascular mechanisms, we assessed microvascular hemodynamics in a model of laser-induced cortical arteriolar thrombosis.
METHODS: The cortical microcirculation of anesthetized, physiologically monitored Sprague-Dawley rats was studied in vivo via a frontoparietal cranial window (intact dura) by two-photon laser-scanning microscopy after plasma-labeling with fluorescein-dextran. Focal thrombosis was produced in 30- to 50-mum cortical arterioles by laser irradiation. Arteriolar flow velocity was measured repeatedly by line-scanning. At 30 minutes post-thrombosis, animals were treated with either human albumin, 2 g/kg, or with saline control.
RESULTS: Baseline arteriolar flow velocity averaged 3.5+/-1.8 mm/s and was reduced to 10% to 13% of control values by laser-induced thrombosis, which also led to focal vasodilatation (mean, 49% above baseline diameter). Saline treatment at 30 minutes post-thrombosis failed to influence arteriolar flow velocity, which remained depressed at 10% to 22% of control throughout the subsequent 60- to 90-minute observation period. By contrast, albumin treatment induced a prompt rise in median flow velocity to 38% of control by 10 minutes post-treatment, and to 61% to 67% of control by 50 to 60 minutes.
CONCLUSIONS: High-dose albumin therapy induces a prompt, sustained improvement in microvascular hemodynamics distal to a cortical arteriolar thrombosis; these data support an important intravascular component to albumin's protective effect in acute cerebral ischemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032741      PMCID: PMC2699114          DOI: 10.1161/STROKEAHA.107.495598

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  28 in total

1.  Remodeling of hippocampal synaptic networks by a brief anoxia-hypoglycemia.

Authors:  Pascal Jourdain; Irina Nikonenko; Stefano Alberi; Dominique Muller
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

2.  Transient oxygen-glucose deprivation induces rapid morphological changes in rat hippocampal dendrites.

Authors:  A Piccini; R Malinow
Journal:  Neuropharmacology       Date:  2001-11       Impact factor: 5.250

3.  Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy.

Authors:  R H Christie; B J Bacskai; W R Zipfel; R M Williams; S T Kajdasz; W W Webb; B T Hyman
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

4.  Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies.

Authors:  Y Liu; L Belayev; W Zhao; R Busto; A Belayev; M D Ginsberg
Journal:  Eur J Pharmacol       Date:  2001-10-05       Impact factor: 4.432

5.  Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses.

Authors:  Ludmila Belayev; Elisabeth Pinard; Helene Nallet; Jacques Seylaz; Yitao Liu; Panomkhawn Riyamongkol; Weizhao Zhao; Raul Busto; Myron D Ginsberg
Journal:  Stroke       Date:  2002-04       Impact factor: 7.914

6.  Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice.

Authors:  Brian J Bacskai; Gregory A Hickey; Jesse Skoch; Stephen T Kajdasz; Yanming Wang; Guo-Feng Huang; Chester A Mathis; William E Klunk; Bradley T Hyman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-29       Impact factor: 11.205

7.  Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse.

Authors:  Shahrokh Falati; Peter Gross; Glenn Merrill-Skoloff; Barbara C Furie; Bruce Furie
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

8.  Trans-synaptic increase of hypoxic tolerance in hippocampus upon physical challenge with two-photon microscopy.

Authors:  Maren Büchner; Roman Huber; Matthias W Riepe
Journal:  Hippocampus       Date:  2002       Impact factor: 3.899

9.  Albumin and hydroxyethyl starch modulate oxidative inflammatory injury to vascular endothelium.

Authors:  John D Lang; Mario Figueroa; Phillip Chumley; Mutay Aslan; John Hurt; Margaret M Tarpey; Beatriz Alvarez; Rafael Radi; Bruce A Freeman
Journal:  Anesthesiology       Date:  2004-01       Impact factor: 7.892

10.  Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor.

Authors:  A Tokumura; J Yoshida; T Maruyama; K Fukuzawa; H Tsukatani
Journal:  Thromb Res       Date:  1987-04-01       Impact factor: 3.944

View more
  22 in total

Review 1.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 2.  Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials.

Authors:  Jialing Liu; Yongting Wang; Yosuke Akamatsu; Chih Cheng Lee; R Anne Stetler; Michael T Lawton; Guo-Yuan Yang
Journal:  Prog Neurobiol       Date:  2013-11-27       Impact factor: 11.685

3.  In vivo real-time two-photon microscopic imaging of platelet aggregation induced by selective laser irradiation to the endothelium created in the beta-actin-green fluorescent protein transgenic mice.

Authors:  Yuhki Koike; Koji Tanaka; Yoshinaga Okugawa; Yuhki Morimoto; Yuji Toiyama; Keiichi Uchida; Chikao Miki; Akira Mizoguchi; Masato Kusunoki
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

4.  Visualizing the cortical microcirculation in patients with stroke.

Authors:  Myron D Ginsberg
Journal:  Crit Care Med       Date:  2011-05       Impact factor: 7.598

5.  Impaired leptomeningeal collateral flow contributes to the poor outcome following experimental stroke in the Type 2 diabetic mice.

Authors:  Yosuke Akamatsu; Yasuo Nishijima; Chih Cheng Lee; Shih Yen Yang; Lei Shi; Lin An; Ruikang K Wang; Teiji Tominaga; Jialing Liu
Journal:  J Neurosci       Date:  2015-03-04       Impact factor: 6.167

6.  High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial.

Authors:  Myron D Ginsberg; Yuko Y Palesch; Michael D Hill; Renee H Martin; Claudia S Moy; William G Barsan; Bonnie D Waldman; Diego Tamariz; Karla J Ryckborst
Journal:  Lancet Neurol       Date:  2013-09-27       Impact factor: 44.182

7.  The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2.

Authors:  Myron D Ginsberg; Yuko Y Palesch; Renee H Martin; Michael D Hill; Claudia S Moy; Bonnie D Waldman; Sharon D Yeatts; Diego Tamariz; Karla Ryckborst
Journal:  Stroke       Date:  2010-12-16       Impact factor: 7.914

8.  Albumin-Induced Neuroprotection in Focal Cerebral Ischemia in the ALIAS Trial: Does Severity, Mechanism, and Time of Infusion Matter?

Authors:  Rakesh Khatri; Mohammad Rauf Afzal; Gustavo J Rodriguez; Alberto Maud; Muhammad Shah Miran; Mohtashim Arbaab Qureshi; Salvador Cruz-Flores; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

9.  Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways.

Authors:  Hantamalala Ralay Ranaivo; Mark S Wainwright
Journal:  Brain Res       Date:  2009-12-02       Impact factor: 3.252

Review 10.  Multifunctional actions of approved and candidate stroke drugs.

Authors:  Jens Minnerup; Wolf-Rüdiger Schäbitz
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.